BioNTech SE Sponsored ADR BNTX
98.52
(0.74)
(0.75%)
as of 25 Sep
- Market cap
- $24.9B
- P/E
- 0.0×
Follow BNTX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
7.81 | 7.05 | 7.09 | 6.68 | |
P/FCF ratio |
47.08 | 39.95 | 0.00 | 0.00 | |
P/Operating CF |
1,525.76 | (45.68) | 66.76 | 26.47 | |
P/B ratio |
1.14 | 1.03 | 1.06 | 1.09 | |
Price to Tangible BV |
1.27 | 1.15 | 1.18 | 1.21 | |
EV/Sales |
2.24 | 1.80 | 2.00 | 1.95 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
8.91 | 6.78 | 12.56 | (20.16) | |
EV/FCF |
13.49 | 10.17 | (19.85) | (5.60) | |
Quick Ratio |
7.70 | 8.64 | 7.40 | 6.89 | |
Current Ratio |
7.85 | 8.80 | 7.54 | 7.12 | |
Net Debt/EBITDA |
21.18 | 25.78 | 73.50 | (178.52) | |
Debt/Assets |
1.55% | 1.44% | 1.22% | 1.15% | |
Debt/Equity |
0.02 | 0.02 | 0.01 | 0.01 | |
Asset Turnover |
0.13 | 0.14 | 0.13 | 0.14 | |
Operating CF/Net income |
(0.02) | 0.79 | (0.92) | (26.56) | |
Capex/Depreciation |
(0.19) | (0.64) | (0.25) | (0.43) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
521.78% | 471.63% | 59.99% | 37.18% | |
Selling, General and Administrative Expense of Revenue |
187.31% | 127.69% | 25.42% | 9.78% | |
Intangible Assets out of Total Assets |
0.09 | 0.09 | 0.09 | 0.08 | |
Share Based Compensation of Revenue |
7.35% | 17.53% | 1.84% | 1.63% | |
Graham Net Nets |
0.63 | 0.68 | 0.66 | 0.64 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(8.41%) | (6.62%) | (5.50%) | (2.67%) | |
Free Cash Flow Yield |
2.12% | 2.50% | (1.42%) | (5.22%) | |
Revenue per Share |
0.48 | 0.55 | 4.07 | 7.42 | |
Operating CF per Share |
0.06 | (1.95) | 1.43 | 3.73 | |
Capex per Share |
(0.24) | (0.36) | (0.18) | (0.27) | |
Free Cash Flow per Share |
(0.18) | (2.30) | 1.24 | 3.46 | |
Cash per Share |
67.83 | 67.65 | 69.64 | 71.00 | |
Shareholders Equity per Share |
81.50 | 86.41 | 89.99 | 90.31 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
81.50 | 86.41 | 89.99 | 90.31 | |
Free Cash Flow |
(44.42) | (583.21) | 300.71 | 827.64 | |
Working Capital |
15,519.84 | 16,112.66 | 15,844.46 | 15,906.63 | |
Capital Expenditures |
(59.87) | (90.47) | (43.97) | (63.54) | |
Net Current Asset Value |
14,780.47 | 15,397.20 | 15,140.62 | 15,157.01 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.49 | 0.65 | 0.04 | 0.04 | |
Net Profit Margin |
(777.27%) | (450.38%) | (38.14%) | (1.89%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
952.71 | 888.76 | 1,371.67 | 1,111.96 | |
Average Payables |
662.14 | 508.11 | 533.46 | 652.94 | |
Average Inventory |
189.43 | 194.75 | 215.90 | 298.55 | |
Average Assets |
24,107.67 | 23,490.40 | 24,628.65 | 24,788.99 | |
Average Common Equity |
20,826.82 | 20,911.54 | 21,377.51 | 21,308.22 |
Columns are period end dates